Shares of Sanofi SA (NYSE:SNY) have been assigned a consensus recommendation of “Hold” from the fourteen brokerages that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, nine have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $51.50.
SNY has been the subject of several research reports. Zacks Investment Research downgraded Sanofi from a “hold” rating to a “strong sell” rating in a research note on Friday, October 6th. Morgan Stanley downgraded Sanofi from an “overweight” rating to an “underweight” rating in a research note on Friday, December 1st. Nord/LB restated a “neutral” rating on shares of Sanofi in a research note on Wednesday, December 27th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a research note on Thursday, December 14th. Finally, Barclays upgraded Sanofi from an “underweight” rating to an “equal weight” rating in a research note on Wednesday, November 15th.
A number of hedge funds and other institutional investors have recently made changes to their positions in SNY. State of Tennessee Treasury Department bought a new position in Sanofi in the 2nd quarter valued at about $2,548,000. LSV Asset Management lifted its position in Sanofi by 34.7% in the 2nd quarter. LSV Asset Management now owns 188,300 shares of the company’s stock valued at $9,021,000 after acquiring an additional 48,500 shares in the last quarter. BlackRock Inc. lifted its position in Sanofi by 47.6% in the 2nd quarter. BlackRock Inc. now owns 2,235,422 shares of the company’s stock valued at $107,100,000 after acquiring an additional 720,523 shares in the last quarter. Investment Centers of America Inc. bought a new position in Sanofi in the 2nd quarter valued at about $300,000. Finally, Strategic Global Advisors LLC lifted its position in Sanofi by 0.6% in the 2nd quarter. Strategic Global Advisors LLC now owns 8,632 shares of the company’s stock valued at $414,000 after acquiring an additional 54 shares in the last quarter. 9.08% of the stock is currently owned by institutional investors and hedge funds.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.